☰

Andrew S. Dixon, Ph.D. - Publications

Affiliations: 
2011 Pharmaceutics and Pharmaceutical Chemistry University of Utah, Salt Lake City, UT 
Area:
Pharmacy, Biochemistry, Oncology
Tree Info Similar researchers PubMed Report error

13 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Radford DC, Yang J, Doan MC, Li L, Dixon AS, Owen SC, Kopeček J. Multivalent HER2-binding polymer conjugates facilitate rapid endocytosis and enhance intracellular drug delivery. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 31899273 DOI: 10.1016/J.Jconrel.2019.12.049  0.344
2017 Schwinn MK, Machleidt T, Zimmerman K, Eggers CT, Dixon AS, Hurst R, Hall MP, Encell LP, Binkowski BF, Wood KV. CRISPR-Mediated Tagging of Endogenous Proteins with a Luminescent Peptide. Acs Chemical Biology. PMID 28892606 DOI: 10.1021/Acschembio.7B00549  0.351
2017 Dixon AS, Kim SJ, Baumgartner BK, Krippner S, Owen SC. A Tri-part Protein Complementation System Using Antibody-Small Peptide Fusions Enables Homogeneous Immunoassays. Scientific Reports. 7: 8186. PMID 28811487 DOI: 10.1038/S41598-017-07569-Y  0.324
2015 Binkowski B, Dixon AS, Schwinn MK, Hall MP, Zimmerman K, Otto P, Lubben T, Butler B, Kirkland T, Wood MG, Encell LP, Fan F, Wood KV. Abstract 1998: A novel luminescent system for monitoring intracellular protein:protein interactions Cancer Research. 75: 1998-1998. DOI: 10.1158/1538-7445.Am2015-1998  0.315
2013 Okal A, Mossalam M, Matissek KJ, Dixon AS, Moos PJ, Lim CS. A chimeric p53 evades mutant p53 transdominant inhibition in cancer cells. Molecular Pharmaceutics. 10: 3922-33. PMID 23964676 DOI: 10.1021/Mp400379C  0.593
2012 Dixon AS, Miller GD, Bruno BJ, Constance JE, Woessner DW, Fidler TP, Robertson JC, Cheatham TE, Lim CS. Correction to "improved coiled-coil design enhances interaction with bcr-abl and induces apoptosis". Molecular Pharmaceutics. 9: 1535. PMID 22444272 DOI: 10.1021/Mp300089A  0.691
2012 Dixon AS, Constance JE, Tanaka T, Rabbitts TH, Lim CS. Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifs. Pharmaceutical Research. 29: 1098-109. PMID 22183511 DOI: 10.1007/S11095-011-0654-8  0.712
2012 Dixon AS, Miller GD, Bruno BJ, Constance JE, Woessner DW, Fidler TP, Robertson JC, Cheatham TE, Lim CS. Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis. Molecular Pharmaceutics. 9: 187-95. PMID 22136227 DOI: 10.1021/Mp200461S  0.717
2011 Dixon AS, Pendley SS, Bruno BJ, Woessner DW, Shimpi AA, Cheatham TE, Lim CS. Disruption of Bcr-Abl coiled coil oligomerization by design. The Journal of Biological Chemistry. 286: 27751-60. PMID 21659527 DOI: 10.1074/Jbc.M111.264903  0.603
2011 Woessner DW, Dixon AS, Lim CS. Abstract 1780: Potentiating chronic myeloid leukaemia treatment using oligomeric disruption and RNAi Cancer Research. 71: 1780-1780. DOI: 10.1158/1538-7445.Am2011-1780  0.606
2010 Mossalam M, Dixon AS, Lim CS. Controlling subcellular delivery to optimize therapeutic effect. Therapeutic Delivery. 1: 169-93. PMID 21113240 DOI: 10.4155/Tde.10.8  0.675
2010 Dixon AS, Lim CS. The nuclear translocation assay for intracellular protein-protein interactions and its application to the Bcr coiled-coil domain. Biotechniques. 49: 519-24. PMID 20615205 DOI: 10.2144/000113452  0.571
2009 Dixon AS, Kakar M, Schneider KM, Constance JE, Paullin BC, Lim CS. Controlling subcellular localization to alter function: Sending oncogenic Bcr-Abl to the nucleus causes apoptosis. Journal of Controlled Release : Official Journal of the Controlled Release Society. 140: 245-9. PMID 19576252 DOI: 10.1016/J.Jconrel.2009.06.026  0.715
Show low-probability matches.